Deerfield Discovery and Development (3DC)
Deerfield’s internal research and development engine, 3DC, seeks to advance early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic for the benefit of patients.
3DC is a company-building R&D engine.
Deerfield Discovery and Development (3DC) is a partner to various stakeholders in the biotech ecosystem, including principal investigators in Deerfield’s academic collaboration network, startups, and biopharma companies.
Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide.
3DC is led by Chief Executive Officer Frank Nestle, MD.
Deeply experienced drug hunters seek to advance a competitive portfolio of high-impact medicines
Working with Entrepreneurs
3DC offers turnkey drug discovery expertise and capabilities to founders to advance the therapeutic development of small molecules and biologics.
Instead of building an R&D team from scratch, Deerfield-backed startups can leverage 3DC to advance development plans faster and in collaboration with seasoned biotech and pharma veterans on staff.
Partnering with Biopharma
Deerfield’s infrastructure can support the development of compelling assets on behalf of or in partnership with strategics and corporate partners.
Our team can acquire, transform, mature, and integrate development-stage and commercial assets prior to or in preparation for a corporate acquisition.
.jpg)
Laboratory Space at Cure
3DC scientists enjoy access to in-building laboratory facilities including state-of-the-art equipment like cryo-EM, NMR, flow cytometry, automated screening robots, and high-throughput mass spectrometry.
Deerfield partners with leading academic research centers, aiming to provide critical funding and expertise to sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
In May 2020, Deerfield and the University of Michigan announced a new partnership to create a company called Great Lakes Discovery. Great Lakes Discovery aims to commercialize therapeutic projects that hold promise in solving unmet medical needs.
In December 2019, Deerfield and Duke University announced the creation of a major research collaboration, Four Points Innovation. Spearheaded by Duke University’s Office of Licensing & Ventures, the alliance is expected to accelerate the preclinical development of new drugs for improved quality of life and cures for diseases.
In September 2022, Beth Israel Deaconess Medical Center (BIDMC) and Deerfield Management announced a research collaboration aimed at accelerating the discovery of novel therapeutics. Through a newly formed company called Brookline Avenue Innovations, LLC, Deerfield has committed up to $130 million, along with additional scientific and operational support, to advance BIDMC research that has the potential to transform patient care over the next decade.
In October 2017, Deerfield launched a partnership with the Broad Institute of MIT and Harvard. The Broad Institute is a highly integrated biomedical and genomic research center that includes more than three thousand scientists committed to advancing research in areas such as infectious disease, cancer, psychiatric research and cardiovascular disease.
In May 2021, Deerfield and Baylor College of Medicine announced a major research collaboration to advance promising therapeutics and support pharmaceutical research and discovery. The collaboration called Blue Square Discoveries will expand the resources and expertise available to Baylor to further advance discoveries beyond the laboratory.
In October 2017, Deerfield and The Johns Hopkins University entered into a collaboration by creating Bluefield Innovations, which is designed to catalyze the development of early stage therapeutics.